Participated · Seed · Apr 2026

Q-Factor was founded in 2026 by four leading physicists from the Weizmann Institute of Science and the Technion and had operated in stealth before its public emergence. The company is developing a full-scale quantum computer using neutral atom technology and says it has identified architectural bottlenecks in existing systems. Its stated goal is to enable continuous scalability of neutral-atom systems toward and beyond one million qubits. Founders include Prof. Nir Davidson, Prof. Ofer Firstenberg, Prof. Yoav Sagi, and Dr. Guy Raz, bringing deep academic and technical leadership to the venture. Q-Factor is backed by a $24 million Seed round and a grant from the Israel Innovation Authority, and counts institutional investors and the founders' academic institutions among its shareholders.

Participated · Seed · Mar 2026

Sub-Q Bionics is developing a next-generation implantable lymphatic drainage system—described as bionic lymph node technology—intended to manage lymphedema by assisting lymphatic circulation beneath the skin. The technology is founded on scientific innovations from the Weizmann Institute of Science and Shamir Medical Center, and Yeda supported the company through its WIN venture creation platform. The company is headquartered in Stillwater, Minnesota. Its intended system aims to provide automatic fluid management and reduce symptoms such as pain, swelling, and mobility limitations for patients living with lymphedema. Sub-Q Bionics recently closed a $1.5 million pre-seed round to advance development toward pre-clinical milestones and to build regulatory and commercial plans. The company expects to open a seed round in Q2 2026.

Participated · Series A · Mar 2026

Scala Biodesign builds ScalaOS, a production-grade protein design platform that integrates physics-based modeling, evolutionary data, and LLM-based AI models to optimize protein performance. The platform targets applications across antibodies, enzymes, vaccines, diagnostics, and industrial biotechnology, and aims to reduce experimental iterations by producing higher-performing designs often in a single design cycle. Over the past eight months ScalaOS has onboarded nine of the world’s top 20 pharmaceutical companies and engaged leading chemical corporations. A highlighted collaboration with Boehringer Ingelheim reportedly stabilized multiple challenging drug targets, improving expression and activity to advance discovery programs. Scala was founded in 2022 by Dr. Ravit Netzer and Dr. Adi Goldenzweig, with Chief Scientist Prof. Sarel Fleishman, and is based in Tel Aviv, Israel. The company has translated more than a decade of validated protein design research and 150+ publications into an enterprise-ready software platform for industry R&D.

Participated · Seed · Mar 2026

LumenGuides is developing NaviScope, an autonomous robotic bronchoscopic navigation platform that integrates Fiber Bragg Grating (FBG) shape and force sensing with proprietary navigation algorithms to generate a roadmap from pre-procedural imaging. The system is designed to enable precise access to early-stage, peripheral lung lesions while reducing reliance on continuous fluoroscopy and radiation exposure. The company has completed a functional prototype and conducted a successful animal study at Shamir Medical Center (Assaf Harofeh), and it has established clinical collaborations both in Israel and internationally. The recent Seed financing and Israel Innovation Authority grant will fund acceleration of its clinical and regulatory roadmap and preparations for First-in-Human trials targeted for May 2026. No revenue, user, or valuation figures were disclosed in the articles.

Participated · Grant · Dec 2025

Founded in 2024, Moonshot Space is developing a high-power electromagnetic accelerator that can hurl payloads at up to 8 kilometres per second, eliminating the need for onboard propellant. The company is targeting two primary markets: low-cost, rapid-turnaround cargo delivery to orbit and high-cadence hypersonic testing up to Mach 6. Its technology promises to boost the useful payload fraction of small launches from about 4 % to more than 45 %, enabling economical resupply of satellites, private stations and in-orbit manufacturing facilities. Preliminary agreements have already been signed with Italian in-orbit services firm D-Orbit and U.S. refuelling startup Orbit Fab. Moonshot’s first full-scale accelerator is under construction in Caesarea, Israel, and the 32-person team includes veterans from Iron Dome, David’s Sling, JFrog and the Israeli space program. For defence customers, the company aims to shift from one hypersonic test per week to several per day, dramatically reducing cost and schedule. To finance these plans, Moonshot has raised $12 million to date, comprising $11 million in equity and a $1 million grant from the Israel Innovation Authority. Rather than compete with full rocket launches, the startup intends to serve as a complementary logistics link for sub-scale payloads and on-orbit refuelling missions.